Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Ondansetron
CST Pharma Ltd
A04AA01
Ondansetron
16mg
Suppository
Rectal
No Controlled Drug Status
Valid as a prescribable product
BNF: 04060000; GTIN: 5055946806266
ZOFRAN ® 16MG SUPPOSITORIES (ondansetron) PACKAGE LEAFLET: INFORMATION FOR THE USER READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions about your illness or your medicine, ask your doctor, nurse or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist. This includes any other side effects not listed in this leaflet. See section 4. The name of your medicine is Zofran 16mg Suppositories but will be referred to as Zofran suppositories throughout this leaflet. WHAT IS IN THIS LEAFLET: 1. What Zofran suppositories are and what they are used for 2. What you need to know before you use Zofran suppositories 3. How to use Zofran suppositories 4. Possible side effects 5. How to store Zofran suppositories 6. Contents of the pack and other information 1. WHAT ZOFRAN SUPPOSITORIES ARE AND WHAT THEY ARE USED FOR Zofran suppositories contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics. ZOFRAN SUPPOSITORIES ARE FOR USE IN YOUR BACK PASSAGE ONLY (RECTAL USE). THEY SHOULD NOT BE SWALLOWED. Zofran suppositories are used for: - preventing nausea and vomiting caused by chemotherapy or radiotherapy for cancer Ask your doctor, nurse or pharmacist if you would like any further explanation about these uses. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ZOFRAN SUPPOSITORIES DO NOT USE ZOFRAN SUPPOSITORIES IF: - you are taking apomorphine (used to treat Parkinson’s disease) - you are allergic (hypersensitive) to ondansetron or Witespol S58 in Zofran suppositories If you are not sure, talk to your doctor, nurse or pharmacist before using Zofran suppositories. WARNINGS AND PRECAUTIONS Check with your doc Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zofran Suppositories 16 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 16 mg of ondansetron. 3 PHARMACEUTICAL FORM White torpedo shaped suppositories. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _Adults: _ Zofran Suppositories are indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults: _ The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge. _Emetogenic chemotherapy and radiotherapy: _Zofran can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration. For rectal administration: The recommended dose of Zofran (ondansetron) Suppositories is one 16 mg suppository given 1 to 2 hours before treatment. To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with Zofran should be continued for up to 5 days after a course of treatment. The recommended daily dose for rectal administration is one 16 mg suppository. _Highly emetogenic chemotherapy (e.g. high dose cisplatin):_ Zofran can be given either by oral, rectal, intravenous or intramuscular administration. For rectal administration: The recommended dose of Zofran (ondansetron) Suppositories is one 16 mg suppository given 1 to 2 hours before treatment. The efficacy of Zofran in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate 20 mg, administered prior to chemotherapy. To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with Zofran should be continued for up to 5 days after a course of treatment. The recommended daily dose for rectal administration is one 16 mg suppository. _Paediatric Population Read the complete document